• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Achilles Therapeutics plc (Amendment)

    2/13/24 6:40:57 PM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACHL alert in real time by email
    SC 13G/A 1 d782156dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Achilles Therapeutics plc

    (Name of Issuer)

    American Depositary Shares and Ordinary Shares, nominal value £0.001 per share

    (Title of Class of Securities)

    00449L102 **

    (CUSIP Number)

    December 31, 2023

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    **

    There is no CUSIP number assigned to the ordinary shares. CUSIP number 00449L102 has been assigned to the American Depositary Shares of the Issuer, which are quoted on the Nasdaq Global Select Market under the symbol “ACHL.” Each American Depositary Share represents the right to receive one ordinary share.

     

     

     


       SCHEDULE 13G/A   
    CUSIP No. 00449L102      

     

     1   

     Names of Reporting Person:

     

     Syncona Portfolio Limited

     2  

     Check the appropriate box if a member of a Group (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     Guernsey

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5   

     Sole Voting Power

     

     0

       6  

     Shared Voting Power

     

     11,086,909 (1)

       7  

     Sole Dispositive Power

     

     0

       8  

     Shared Dispositive Power

     

     11,086,909 (1)

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     11,086,909 (1)

    10  

     Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

    11  

     Percent of class represented by amount in row (9)

     

     27.2% (2)

    12  

     Type of Reporting Person (See Instructions)

     

     CO

     

    (1)

    Consists of 11,086,909 American Depositary Shares (“ADSs”) held directly by Syncona Portfolio Limited. Each ADS represents one ordinary share, nominal value £0.001 per share, of the Issuer. The ordinary shares and the ADSs are collectively referred to as the “Ordinary Shares”.

    (2)

    Based on 40,782,948 Ordinary Shares outstanding as of September 30, 2023 as reported in the Issuer’s Form 6-K filed with the Securities and Exchange Commission (the “SEC”) on November 13, 2023.

     

    Page 2 of 12


       SCHEDULE 13G/A   
    CUSIP No. 00449L102      

     

     1   

     Names of Reporting Person:

     

     Syncona Holdings Limited

     2  

     Check the appropriate box if a member of a Group (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     Guernsey

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5   

     Sole Voting Power

     

     0

       6  

     Shared Voting Power

     

     11,086,909 (1)

       7  

     Sole Dispositive Power

     

     0

       8  

     Shared Dispositive Power

     

     11,086,909 (1)

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     11,086,909 (1)

    10  

     Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

    11  

     Percent of class represented by amount in row (9)

     

     27.2% (2)

    12  

     Type of Reporting Person (See Instructions)

     

     CO

     

    (1)

    Consists of 11,086,909 ADSs held directly by Syncona Portfolio Limited. Each ADS represents one ordinary share, nominal value £0.001 per share, of the Issuer.

    (2)

    Based on 40,782,948 Ordinary Shares outstanding as of September 30, 2023 as reported in the Issuer’s Form 6-K filed with the SEC on November 13, 2023.

     

    Page 3 of 12


       SCHEDULE 13G/A   
    CUSIP No. 00449L102      

     

     1   

     Names of Reporting Person:

     

     Syncona Investment Management Limited

     2  

     Check the appropriate box if a member of a Group (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     United Kingdom

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5   

     Sole Voting Power

     

     0

       6  

     Shared Voting Power

     

     11,086,909 (1)

       7  

     Sole Dispositive Power

     

     0

       8  

     Shared Dispositive Power

     

     11,086,909 (1)

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     11,086,909 (1)

    10  

     Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

    11  

     Percent of class represented by amount in row (9)

     

     27.2% (2)

    12  

     Type of Reporting Person (See Instructions)

     

     CO

     

    (1)

    Consists of 11,086,909 ADSs held directly by Syncona Portfolio Limited. Each ADS represents one ordinary share, nominal value £0.001 per share, of the Issuer.

    (2)

    Based on 40,782,948 Ordinary Shares outstanding as of September 30, 2023 as reported in the Issuer’s Form 6-K filed with the SEC on November 13, 2023.

     

    Page 4 of 12


       SCHEDULE 13G/A   
    CUSIP No. 00449L102      

     

     1   

     Names of Reporting Person:

     

     Syncona Limited

     2  

     Check the appropriate box if a member of a Group (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     Guernsey

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5   

     Sole Voting Power

     

     0

       6  

     Shared Voting Power

     

     11,086,909 (1)

       7  

     Sole Dispositive Power

     

     0

       8  

     Shared Dispositive Power

     

     11,086,909 (1)

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     11,086,909 (1)

    10  

     Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

    11  

     Percent of class represented by amount in row (9)

     

     27.2% (2)

    12  

     Type of Reporting Person (See Instructions)

     

     CO

     

    (1)

    Consists of 11,086,909 ADSs held directly by Syncona Portfolio Limited. Each ADS represents one ordinary share, nominal value £0.001 per share, of the Issuer.

    (2)

    Based on 40,782,948 Ordinary Shares outstanding as of September 30, 2023 as reported in the Issuer’s Form 6-K filed with the SEC on November 13, 2023.

     

    Page 5 of 12


       SCHEDULE 13G/A   
    CUSIP No. 00449L102      

     

     1   

     Names of Reporting Person:

     

     Roel Bulthuis

     2  

     Check the appropriate box if a member of a Group (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     Netherlands

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5   

     Sole Voting Power

     

     0

       6  

     Shared Voting Power

     

     11,086,909 (1)

       7  

     Sole Dispositive Power

     

     0

       8  

     Shared Dispositive Power

     

     11,086,909 (1)

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     11,086,909 (1)

    10  

     Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

    11  

     Percent of class represented by amount in row (9)

     

     27.2% (2)

    12  

     Type of Reporting Person (See Instructions)

     

     IN

     

    (1)

    Consists of 11,086,909 ADSs held directly by Syncona Portfolio Limited. Each ADS represents one ordinary share, nominal value £0.001 per share, of the Issuer.

    (2)

    Based on 40,782,948 Ordinary Shares outstanding as of September 30, 2023 as reported in the Issuer’s Form 6-K filed with the SEC on November 13, 2023.

     

    Page 6 of 12


       SCHEDULE 13G/A   
    CUSIP No. 00449L102      

     

     1   

     Names of Reporting Person:

     

     Christopher Hollowood

     2  

     Check the appropriate box if a member of a Group (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     United Kingdom

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5   

     Sole Voting Power

     

     0

       6  

     Shared Voting Power

     

     11,086,909 (1)

       7  

     Sole Dispositive Power

     

     0

       8  

     Shared Dispositive Power

     

     11,086,909 (1)

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     11,086,909 (1)

    10  

     Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

    11  

     Percent of class represented by amount in row (9)

     

     27.2% (2)

    12  

     Type of Reporting Person (See Instructions)

     

     IN

     

    (1)

    Consists of 11,086,909 ADSs held directly by Syncona Portfolio Limited. Each ADS represents one ordinary share, nominal value £0.001 per share, of the Issuer.

    (2)

    Based on 40,782,948 Ordinary Shares outstanding as of September 30, 2023 as reported in the Issuer’s Form 6-K filed with the SEC on November 13, 2023.

     

    Page 7 of 12


    Item 1.

     

    (a)

    Name of Issuer: Achilles Therapeutics plc

     

    (b)

    Address of Issuer’s principal executive offices: 245 Hammersmith Road, London W6 8PW, United Kingdom

     

    Item 2.

     

    (a)

    Name of reporting persons filing:

     

      (i)

    Syncona Portfolio Limited;

     

      (ii)

    Syncona Holdings Limited;

     

      (iii)

    Syncona Investment Management Limited;

     

      (iv)

    Syncona Limited;

     

      (v)

    Roel Bulthuis; and

     

      (vi)

    Christopher Hollowood

     

    (b)

    Address of principal business office or, if none, residence:

    The address of the principal business office of Syncona Portfolio Limited, Syncona Holdings Limited and Syncona Limited is Frances House, PO Box 273, Sir William Place, St. Peter Port, Guernsey, GY1 3RD, Channel Islands. The address of the principal business office of Syncona Investment Management Limited, Roel Bulthuis and Christopher Hollowood is 2nd Floor, 8 Bloomsbury Street, London WC1B 3SR, United Kingdom.

     

    (c)

    Citizenship:

    Syncona Portfolio Limited, Syncona Holdings Limited and Syncona Limited’s citizenship is Guernsey. Syncona Investment Management Limited and Christopher Hollowood’s citizenship is United Kingdom. Roel Bulthuis’ citizenship is the Netherlands.

     

    (d)

    Title and class of securities:

    Ordinary Shares, nominal value £0.001 per share, and American Depositary Shares (“ADS”). Each ADS represents one ordinary share, nominal value £0.001 per share, of the Issuer.

     

    (e)

    CUSIP No.:

    There is no CUSIP number assigned to the ordinary shares. CUSIP number 00449L102 has been assigned to the ADS, which are quoted on the Nasdaq Global Select Market under the symbol “ACHL.”

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.

     

    Item 4.

    Ownership:

    The following information with respect to the ownership of Ordinary Shares of the Issuer by the Reporting Persons filing this statement on Schedule 13G/A is provided as of December 31, 2023:

     

    Page 8 of 12


    Reporting Persons

       Ordinary
    Shares Held
    Directly (1)
         Sole
    Power
    to Vote
    or
    Direct
    the
    Vote (1)
         Shared
    Power to
    Vote or
    Direct the
    Vote (1)
         Sole
    Power to
    Dispose or
    Direct the
    Disposition
    (1)
         Shared
    Power to
    Dispose or
    Direct the
    Disposition
    (1)
         Amount
    Beneficially
    Owned (1)
         Percentage
    of Class (2)
     

    Syncona Portfolio Limited

         11,086,909        0        11,086,909        0        11,086,909        11,086,909        27.2 % 

    Syncona Holdings Limited

         0        0        11,086,909        0        11,086,909        11,086,909        27.2 % 

    Syncona Investment Management Limited

         0        0        11,086,909        0        11,086,909        11,086,909        27.2 % 

    Syncona Limited

         0        0        11,086,909        0        11,086,909        11,086,909        27.2 % 

    Roel Bulthuis

         0        0        11,086,909        0        11,086,909        11,086,909        27.2 % 

    Christopher Hollowood

         0        0        11,086,909        0        11,086,909        11,086,909        27.2 % 

     

    (1)

    Consists of 11,086,909 ADSs held directly by Syncona Portfolio Limited. Each ADS represents one ordinary share, nominal value £0.001 per share, of the Issuer. The ordinary shares and the ADS are collectively referred to as the “Ordinary Shares”.

    (2)

    The percentage of outstanding Ordinary Shares of the Issuer beneficially owned was calculated based on 40,782,948 Ordinary Shares outstanding as of September 30, 2023 as reported in the Issuer’s Form 6-K filed with the Securities and Exchange Commission on November 13, 2023.

    The shares are owned directly by Syncona Portfolio Limited (“Syncona Portfolio”) and indirectly by Syncona Holdings Limited (“Syncona Holdings”), Syncona Limited (“Syncona Limited”), Roel Bulthuis and Christopher Hollowood. Syncona Portfolio is a wholly owned subsidiary of Syncona Holdings, and Syncona Holdings is a wholly controlled subsidiary of Syncona Limited, a publicly-listed company. Investment and voting decisions with respect to these shares are made by Syncona Portfolio, acting upon the recommendation of Roel Bulthuis and Christopher Hollowood, who comprise the investment committee of Syncona Investment Management Limited, also a subsidiary of Syncona Holdings. On November 16, 2023, Roel Bulthuis replaced Martin Murphy on the investment committee of Syncona Investment Management Limited. Each of these entities disclaims beneficial ownership except to the extent of its pecuniary interest therein, if any.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6.

    Ownership of more than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.

    Not applicable.

     

    Item 8.

    Identification and classification of members of the group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certifications.

    Not applicable.

     

    Page 9 of 12


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 13, 2024

     

    SYNCONA PORTFOLIO LIMITED
    By:  

    /s/ Robert Hutchinson

    Name:   Robert Hutchinson
    Title:   Director
    SYNCONA HOLDINGS LIMITED
    By:  

    /s/ Robert Hutchinson

    Name:   Robert Hutchinson
    Title:   Director
    SYNCONA INVESTMENT MANAGEMENT LIMITED
    By:  

    /s/ Christopher Hollowood

    Name:   Christopher Hollowood
    Title:   CEO
    SYNCONA LIMITED
    By:  

    /s/ Robert Hutchinson

    Name:   Robert Hutchinson
    Title:   Director
        

    /s/ Roel Bulthuis

      Roel Bulthuis
     

    /s/ Christopher Hollowood

      Christopher Hollowood

     

    Page 10 of 12


    Exhibit(s):

     

    Exhibit 99.1:    Joint Filing Statement

     

    Page 11 of 12

    Get the next $ACHL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACHL

    DatePrice TargetRatingAnalyst
    4/5/2024$8.00 → $2.00Overweight → Neutral
    Piper Sandler
    More analyst ratings

    $ACHL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Achilles Therapeutics Announces Voluntary Nasdaq Delisting and SEC Deregistration

    LONDON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL) (the Company) today announced that it has formally notified The Nasdaq Stock Market LLC (Nasdaq) of its intention to voluntarily delist its American Depositary Shares (ADSs) from Nasdaq and its intent to deregister its ADSs from the Securities and Exchange Commission (SEC) under Section 12(b) of the Securities Exchange Act of 1934 (Exchange Act). As previously reported, the Company has called a General Meeting for March 20, 2025 to obtain shareholder approval to commence a members' voluntary liquidation. The planned delisting of the ADSs is being undertaken in connection with the contemplated liquidation. Th

    2/28/25 7:00:00 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca

    - Proprietary data and samples from TRACERx and Achilles' Material Acquisition Platform (MAP) will be transferred to AstraZeneca under the Transaction - - Conclusion of Strategic Review - LONDON, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL) today announced that it has transferred the commercial license of data and samples from the TRACERx® Non-Small Cell Lung Cancer (NSCLC) study to AstraZeneca (NASDAQ:AZN). TRACERx (TRAcking Cancer Evolution through therapy (Rx)), led by Professor Charles Swanton at University College London (UCL), UK, is one of the largest tumor evolution studies to generate deep sequencing multi-region and multi-time-point genetic data

    12/24/24 9:30:00 AM ET
    $ACHL
    $AZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market

    LONDON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL) today announced that on November 15, 2024, the Listing Qualifications department of the Nasdaq Stock Market LLC ("Nasdaq") approved the Company's request to transfer the listing of the Company's American Depositary Shares (the "ADSs") from the Nasdaq Global Market to the Nasdaq Capital Market. The transfer is expected to take effect at the opening of business on November 19, 2024. The transfer of the Company's listing to the Nasdaq Capital Market is not expected to have any impact on trading in the Company's ADSs. The Company's ADSs will continue to trade under the symbol "ACHL." The approval by Nasdaq w

    11/19/24 7:00:00 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Achilles Therapeutics downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Achilles Therapeutics from Overweight to Neutral and set a new price target of $2.00 from $8.00 previously

    4/5/24 7:22:16 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHL
    SEC Filings

    View All

    SEC Form 15-12G filed by Achilles Therapeutics plc

    15-12G - Achilles Therapeutics plc (0001830749) (Filer)

    3/21/25 9:41:03 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Achilles Therapeutics plc

    6-K - Achilles Therapeutics plc (0001830749) (Filer)

    3/20/25 5:30:00 PM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 POS filed by Achilles Therapeutics plc

    S-8 POS - Achilles Therapeutics plc (0001830749) (Filer)

    3/19/25 4:16:04 PM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHL
    Leadership Updates

    Live Leadership Updates

    View All

    Achilles Therapeutics Appoints James Taylor as Chief Business Officer and Cassian Yee, MD to Scientific Advisory Board

    LONDON, June 30, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the appointment of James Taylor as Chief Business Officer and Cassian Yee, MD to its Scientific Advisory Board (SAB), effective July 1, 2022. James brings over 25 years of value-creating deal experience that includes global platform and asset deals for pharmaceutical and biotechnology companies. Most recently, he was Chief Business Officer at Sosei Heptares, where he completed a major collaboration with Neurocrine Biosciences for a Phase II-ready M4 agonist for schizophrenia, and led deals

    6/30/22 8:00:00 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Achilles Therapeutics Appoints Bernhard Ehmer to Board of Directors

    LONDON, May 04, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the appointment of Bernhard Ehmer, MD, to the Board as a Non-Executive Director. Bernhard joins Achilles with a strong track record in international R&D, regulatory and commercial activities. Bernhard is a veteran biotechnology and pharmaceutical executive with more than three decades in senior leadership roles. He most recently served as CEO of Biotest AG in Germany and also served as chairman of the board of directors at Symphogen A/S, Denmark until its acquisition by Servier SA in June 2

    5/4/22 8:00:00 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Achilles Therapeutics Strengthens Scientific Advisory Board with Appointment of Alena Gros, Ph.D. and Ben Creelan, M.D.

    LONDON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the appointment of Alena Gros, Ph.D. and Ben Creelan, M.D. to its Scientific Advisory Board (SAB). "We are very pleased to welcome leading experts Dr. Gros and Dr. Creelan to our Scientific Advisory Board. With two ongoing clinical trials, CHIRON in non-small cell lung cancer (NSCLC) and THETIS in melanoma, their extensive research experience and deep clinical expertise with cell-based immunotherapies for the treatment of solid tumors will be invaluable as we continue to advance the clinic

    2/7/22 7:30:00 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHL
    Financials

    Live finance-specific insights

    View All

    Achilles Therapeutics Reports Third Quarter 2024 Financial Results

    – Cash position of $86.1 million as of September 30, 2024, not including cash R&D tax credit of $12.8 million received in October 2024 –         LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL) today announced its financial results for the third quarter ended September 30, 2024, and recent corporate updates. Corporate Updates Following the discontinuation of its TIL-based cNeT program and closure of the Phase I/IIa CHIRON and THETIS clinical trials, the Company has engaged BofA Securities as a financial advisor in the process of exploring strategic options.Achilles Chief Scientific Officer, Sergio Quezada, presented "Targeting Clonal Neoantigens with Pre

    11/14/24 7:00:00 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates

    – Announced research collaboration with Arcturus Therapeutics to explore second-generation mRNA cancer vaccines using Achilles' AI-powered, tumor-targeting technology – – Provided interim Phase I/IIa update on the use of cNeT in Advanced NSCLC and Melanoma including first patients with enhanced host conditioning (EHC), with the first three EHC patients showing improved cNeT persistence and engraftment – – Cash position of $95.1 million supports operations through 2025 – LONDON, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid t

    8/14/24 7:00:00 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

    – Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma – – Evaluating the benefit of enhanced host conditioning with further data expected in 2H 2024 – – Strong cash position of $112.3 million supports operations through 2025 – LONDON, May 08, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the first quarter ended March 31, 2024, and recent business highlights. "Just after the close of the first quarter, we shared the interim Phase I/

    5/8/24 7:00:00 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Achilles Therapeutics plc

    SC 13G/A - Achilles Therapeutics plc (0001830749) (Subject)

    11/14/24 4:23:04 PM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Achilles Therapeutics plc

    SC 13G - Achilles Therapeutics plc (0001830749) (Subject)

    9/25/24 7:14:31 PM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Achilles Therapeutics plc (Amendment)

    SC 13G/A - Achilles Therapeutics plc (0001830749) (Subject)

    3/29/24 4:30:59 PM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care